Literature DB >> 26747246

Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.

Ramesh Choudhari1, Valerio Giacomo Minero1, Matteo Menotti1, Roberta Pulito1, Cord Brakebusch2, Mara Compagno3, Claudia Voena1, Chiara Ambrogio4, Roberto Chiarle5.   

Abstract

Increasing evidence suggests that Rho family GTPases could have a critical role in the biology of T-cell lymphoma. In ALK-rearranged anaplastic large cell lymphoma (ALCL), a specific subtype of T-cell lymphoma, the Rho family GTPases Cdc42 and Rac1 are activated by the ALK oncogenic activity. In vitro studies have shown that Cdc42 and Rac1 control rather similar phenotypes of ALCL biology such as the proliferation, survival, and migration of lymphoma cells. However, their role and possible redundancy in ALK-driven lymphoma development in vivo are still undetermined. We genetically deleted Cdc42 or Rac1 in a mouse model of ALK-rearranged ALCL to show that either Cdc42 or Rac1 deletion impaired lymphoma development, modified lymphoma morphology, actin filament distribution, and migration properties of lymphoma cells. Cdc42 or Rac1 deletion primarily affected survival rather than proliferation of lymphoma cells. Apoptosis of lymphoma cells was equally induced following Cdc42 or Rac1 deletion, was associated with upregulation of the proapoptotic molecule Bid, and was blocked by Bcl2 overexpression. Remarkably, Cdc42/Rac1 double deletion, but not Cdc42 or Rac1 single deletions, completely prevented NPM-ALK lymphoma dissemination in vivo. Thus, Cdc42 and Rac1 have nonredundant roles in controlling ALK-rearranged lymphoma survival and morphology but are redundant for lymphoma dissemination, suggesting that targeting both GTPases could represent a preferable therapeutic option for ALCL treatment.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26747246      PMCID: PMC4786839          DOI: 10.1182/blood-2015-11-683052

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Rho and Rac take center stage.

Authors:  Keith Burridge; Krister Wennerberg
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Rac1 is required for the formation of three germ layers during gastrulation.

Authors:  K Sugihara; N Nakatsuji; K Nakamura; K Nakao; R Hashimoto; H Otani; H Sakagami; H Kondo; S Nozawa; A Aiba; M Katsuki
Journal:  Oncogene       Date:  1998-12-31       Impact factor: 9.867

Review 3.  The biology and management of systemic anaplastic large cell lymphoma.

Authors:  Greg Hapgood; Kerry J Savage
Journal:  Blood       Date:  2015-04-13       Impact factor: 22.113

Review 4.  RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis.

Authors:  Hemant K Bid; Ryan D Roberts; Parmeet K Manchanda; Peter J Houghton
Journal:  Mol Cancer Ther       Date:  2013-09-26       Impact factor: 6.261

5.  NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

Authors:  Roberto Chiarle; Jerald Z Gong; Ilaria Guasparri; Anna Pesci; Jonjing Cai; Jian Liu; William J Simmons; Girish Dhall; Jennifer Howes; Roberto Piva; Giorgio Inghirami
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

6.  Rac GTPases play critical roles in early T-cell development.

Authors:  Celine Dumont; Agnieszka Corsoni-Tadrzak; Sandra Ruf; Jasper de Boer; Adam Williams; Martin Turner; Dimitris Kioussis; Victor L J Tybulewicz
Journal:  Blood       Date:  2008-12-16       Impact factor: 22.113

Review 7.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

8.  Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

Authors:  Rocco Piazza; Vera Magistroni; Angela Mogavero; Federica Andreoni; Chiara Ambrogio; Roberto Chiarle; Luca Mologni; Petra S Bachmann; Richard B Lock; Paola Collini; Giuseppe Pelosi; Carlo Gambacorti-Passerini
Journal:  Neoplasia       Date:  2013-05       Impact factor: 5.715

9.  Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination.

Authors:  A Colomba; S Giuriato; E Dejean; K Thornber; G Delsol; H Tronchère; F Meggetto; B Payrastre; F Gaits-Iacovoni
Journal:  Blood Cancer J       Date:  2011-06-03       Impact factor: 11.037

10.  Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity.

Authors:  Karin Zins; Sandun Gunawardhana; Trevor Lucas; Dietmar Abraham; Seyedhossein Aharinejad
Journal:  J Transl Med       Date:  2013-11-27       Impact factor: 5.531

View more
  11 in total

1.  Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.

Authors:  Chiara Pighi; Taek-Chin Cheong; Mara Compagno; Enrico Patrucco; Maddalena Arigoni; Martina Olivero; Qi Wang; Cristina López; Stephan H Bernhart; Bruno M Grande; Teresa Poggio; Fernanda Langellotto; Lisa Bonello; Riccardo Dall'Olio; Sandra Martínez-Martín; Luca Molinaro; Paola Francia di Celle; Jonathan R Whitfield; Laura Soucek; Claudia Voena; Raffaele A Calogero; Ryan D Morin; Louis M Staudt; Reiner Siebert; Alberto Zamò; Roberto Chiarle
Journal:  Blood Adv       Date:  2021-12-14

2.  Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; Gina L Razidlo; Surendra Dasari; Yu Zeng; Guangzhen Hu; Ryan A Knudson; Patricia T Greipp; Jaime I Davila; Sarah H Johnson; Julie C Porcher; James B Smadbeck; Bruce W Eckloff; Daniel D Billadeau; Paul J Kurtin; Mark A McNiven; Brian K Link; Stephen M Ansell; James R Cerhan; Yan W Asmann; George Vasmatzis; Andrew L Feldman
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

3.  The long non-coding RNA LINC01013 enhances invasion of human anaplastic large-cell lymphoma.

Authors:  I-Hsiao Chung; Pei-Hsuan Lu; Yang-Hsiang Lin; Ming-Ming Tsai; Yun-Wen Lin; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

Review 4.  Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis.

Authors:  Shu Lou; Penglai Wang; Jianrong Yang; Junqing Ma; Chao Liu; Meng Zhou
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

Review 5.  RHO Family GTPases in the Biology of Lymphoma.

Authors:  Claudia Voena; Roberto Chiarle
Journal:  Cells       Date:  2019-06-26       Impact factor: 6.600

6.  The DNA-helicase HELLS drives ALK- ALCL proliferation by the transcriptional control of a cytokinesis-related program.

Authors:  Valentina Fragliasso; Alessia Ciarrocchi; Annalisa Tameni; Elisabetta Sauta; Valentina Mularoni; Federica Torricelli; Gloria Manzotti; Giorgio Inghirami; Riccardo Bellazzi
Journal:  Cell Death Dis       Date:  2021-01-27       Impact factor: 8.469

Review 7.  Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis.

Authors:  Valentina Fragliasso; Annalisa Tameni; Giorgio Inghirami; Valentina Mularoni; Alessia Ciarrocchi
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

8.  The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma.

Authors:  Po-Shuan Huang; I-Hsiao Chung; Yang-Hsiang Lin; Tzu-Kang Lin; Wei-Jan Chen; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2018-05-14       Impact factor: 5.923

9.  miR-16 integrates signal pathways in myofibroblasts: determinant of cell fate necessary for fibrosis resolution.

Authors:  Qin Pan; Can-Jie Guo; Qing-Yang Xu; Jin-Zhi Wang; Han Li; Chun-Hua Fang
Journal:  Cell Death Dis       Date:  2020-08-07       Impact factor: 8.469

Review 10.  Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas.

Authors:  José R Cortés; Teresa Palomero
Journal:  Cold Spring Harb Perspect Med       Date:  2021-05-03       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.